Abstract
The principle of this method was to screen the pharmacological activity of ten prepared polyphyto formulations by using highthroughput screening method for their antihyperlipidemic activity. The study was performed in three stages using single animal, two animals and three animals in a group. The data produced with single animal is compared with the average data shown by two and three experimental animals and further with six animals (one way ANOVA) for the statistical significance and was duly reported. R2 value was determined by Least squares linear regression analysis to interpret as the proportion of the variance in the dependent variable that is predictable from the independent variable. Test formulations were given at 50mg/kg, body weight through p.o. route daily for 14 days in experimental animals induced with hyperlipidemia by injecting Triton X-100 at 100 mg/kg BW i/p and observed for 48 hrs for the development of hyperlipidemia. Two best formulations namely PHF-21 and PHF-26 were selected by highthroughput screening and results repeated in six animals in a group were found to be statically similar.
Keywords: Antihyperlipidemic, ANOVA, highthroughput, linear regression, Triton X-100.
Graphical Abstract
Current Bioactive Compounds
Title:Preliminary Pharmacological Screening of Anti-Hyperlipidemic Polyphyto Combination by Novelistic Highthroughput Screening Method
Volume: 12 Issue: 2
Author(s): Asha Bisht, Satheesh N.V. Madhav and Kumud Upadhyaya
Affiliation:
Keywords: Antihyperlipidemic, ANOVA, highthroughput, linear regression, Triton X-100.
Abstract: The principle of this method was to screen the pharmacological activity of ten prepared polyphyto formulations by using highthroughput screening method for their antihyperlipidemic activity. The study was performed in three stages using single animal, two animals and three animals in a group. The data produced with single animal is compared with the average data shown by two and three experimental animals and further with six animals (one way ANOVA) for the statistical significance and was duly reported. R2 value was determined by Least squares linear regression analysis to interpret as the proportion of the variance in the dependent variable that is predictable from the independent variable. Test formulations were given at 50mg/kg, body weight through p.o. route daily for 14 days in experimental animals induced with hyperlipidemia by injecting Triton X-100 at 100 mg/kg BW i/p and observed for 48 hrs for the development of hyperlipidemia. Two best formulations namely PHF-21 and PHF-26 were selected by highthroughput screening and results repeated in six animals in a group were found to be statically similar.
Export Options
About this article
Cite this article as:
Bisht Asha, N.V. Madhav Satheesh and Upadhyaya Kumud, Preliminary Pharmacological Screening of Anti-Hyperlipidemic Polyphyto Combination by Novelistic Highthroughput Screening Method, Current Bioactive Compounds 2016; 12 (2) . https://dx.doi.org/10.2174/157340721202160504221515
DOI https://dx.doi.org/10.2174/157340721202160504221515 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prader-Willi Syndrome: Clinical Genetics and Diagnostic Aspects with Treatment Approaches
Current Pediatric Reviews Piribedil: Antiparkinsonian Properties and Potential Clinical Utility in Dopaminergic Disorders
Current Drug Therapy Alteration of Structure and Aggregation of α-Synuclein by Familial Parkinson’s Disease Associated Mutations
Current Protein & Peptide Science Catatonia: A Narrative Review
Central Nervous System Agents in Medicinal Chemistry Does Phosphodiesterase 11A (PDE11A) Hold Promise as a Future Therapeutic Target?
Current Pharmaceutical Design Donepezil: An Important Prototype to the Design of New Drug Candidates for Alzheimer’s Disease
Mini-Reviews in Medicinal Chemistry Anti-inflammatory Effects of Mesenchymal Stem Cells and their Secretomes in Pneumonia
Current Pharmaceutical Biotechnology Non-Analgesic Effects of Opioids: Interactions Between Opioids and Other Drugs
Current Pharmaceutical Design Selenite Benefits Embryonic Stem Cells Therapy in Parkinson’s Disease
Current Molecular Medicine Nanotechnology: A Novel Approach for Drug Development in Health Care System
Current Nanomaterials Polymeric Nanocarriers and Nanoreactors: A Survey of Possible Therapeutic Applications
Current Pharmaceutical Design Neuropeptide Y: Role in Emotion and Alcohol Dependence
CNS & Neurological Disorders - Drug Targets Pharmacogenetics of Cytochrome P450 (CYP) 1A2 and Variability in Psychotropic Drug Response
Current Psychiatry Reviews Patients Stratification Strategies to Optimize the Effectiveness of Scavenging Biogenic Aldehydes: Towards a Neuroprotective Approach for Parkinson's Disease
Current Neuropharmacology Efficacy and Cardiovascular Safety of DPP-4 Inhibitors
Current Drug Safety Neurotrophic Factors as a Protective Strategy in Parkinsons Disease
CNS & Neurological Disorders - Drug Targets TRP Channels: New Potential Therapeutic Approaches in CNS Neuropathies
CNS & Neurological Disorders - Drug Targets Glial Reaction in Parkinsons Diseases: Inflammatory Activation Signaling of Glia as a Potential Therapeutic Target
Current Signal Transduction Therapy Application and Interpretation of Genome-Wide Association (GWA) Studies for Informing Pharmacogenomic Research - Examples from the Field of Age-Related Macular Degeneration
Current Molecular Medicine Beneficial Neurobiological Effects of Melatonin Under Conditions of Increased Oxidative Stress
Current Medicinal Chemistry - Central Nervous System Agents